BioSpace News Archive

Delfi Diagnostics, a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has been selected as the liquid lung cancer biopsy partner in Europe’s multi-national, randomized, prospective lung cancer screening trial known as 4-IN-THE-LUNG-RUN, or 4ITLR.

Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces positive confirmatory data from the Phase I trial evaluating TG6002 administered intravenously in combination with oral 5-FC in patients with advanced gastrointestinal carcinomas.

NANOBIOTIX announced reaching an agreement in principle to restructure €30.7 million in outstanding debt obligations related to the Company’s 2018 loan agreement with the European Investment Bank.

Poolbeg Pharma announces that the Company’s Chairman, Cathal Friel, will be attending the HC Wainwright Global Investment Conference, which is taking place from 12-14 September at the Lotte New York Palace Hotel in New York City, NY, USA.

Mirum Pharmaceuticals, Inc. announced that on September 10-11, 2022, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 47,750 shares of common stock and 23,900 restricted stock units to 11 new employees under Mirum’s 2020 Inducement Plan.

Pharnext SA announces that the first patient has been enrolled in the PREMIER Open Label Extension study of PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A in the United States.

Lyell Immunopharma, Inc. announced that a poster describing the first-in-human Phase 1 trial design for LYL797, Lyell’s ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming for the treatment of solid tumors, is being presented today at the European Society for Medical Oncology Congress 2022 in Paris, France.

IRLAB Therapeutics IRLAB, a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, announced that the last participating patient has been randomized and entered the ongoing Phase IIb study of lead candidate mesdopetam.

Keros Therapeutics, Inc. announced that it presented preliminary clinical data from the Part 2 multiple ascending dose portion of its Phase 1 clinical trial of KER-012 in healthy postmenopausal women at the American Society of Bone and Mineral Research 2022 Annual Meeting on Sunday, September 11, 2022.

EpiVax, Inc. is pleased to announce the award of a two-year, $2 million grant from the FDA’s Office of Center for Drug Evaluation and Research to validate a method for immunogenicity risk assessment of host cell proteins for improving biosimilar product development and assessing product interchangeability.